CMRX Stock Overview
Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$5.65|
|52 Week High||US$11.57|
|52 Week Low||US$3.41|
|1 Month Change||-3.91%|
|3 Month Change||-18.00%|
|1 Year Change||56.08%|
|3 Year Change||71.73%|
|5 Year Change||9.28%|
|Change since IPO||-69.93%|
Recent News & Updates
Is Chimerix (NASDAQ:CMRX) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
|CMRX||US Biotechs||US Market|
Return vs Industry: CMRX exceeded the US Biotechs industry which returned 1.8% over the past year.
Return vs Market: CMRX exceeded the US Market which returned 19.4% over the past year.
|CMRX Average Weekly Movement||8.0%|
|Biotechs Industry Average Movement||8.8%|
|Market Average Movement||6.1%|
|10% most volatile stocks in US Market||14.8%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: CMRX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: CMRX's weekly volatility has decreased from 13% to 8% over the past year.
About the Company
Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox; dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy; and ONC201 a program for potentially treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications.
Chimerix Fundamentals Summary
|CMRX fundamental statistics|
Is CMRX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CMRX income statement (TTM)|
|Cost of Revenue||US$48.17m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.67|
|Net Profit Margin||-4,762.95%|
How did CMRX perform over the long term?See historical performance and comparison
Is Chimerix undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CMRX ($5.65) is trading below our estimate of fair value ($101.73)
Significantly Below Fair Value: CMRX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CMRX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: CMRX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CMRX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CMRX is overvalued based on its PB Ratio (4.7x) compared to the US Biotechs industry average (2.8x).
How is Chimerix forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CMRX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: CMRX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CMRX's is expected to become profitable in the next 3 years.
Revenue vs Market: CMRX's revenue (51.6% per year) is forecast to grow faster than the US market (10% per year).
High Growth Revenue: CMRX's revenue (51.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CMRX's Return on Equity is forecast to be high in 3 years time
How has Chimerix performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CMRX is currently unprofitable.
Growing Profit Margin: CMRX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CMRX is unprofitable, and losses have increased over the past 5 years at a rate of 9.9% per year.
Accelerating Growth: Unable to compare CMRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CMRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).
Return on Equity
High ROE: CMRX has a negative Return on Equity (-139.04%), as it is currently unprofitable.
How is Chimerix's financial position?
Financial Position Analysis
Short Term Liabilities: CMRX's short term assets ($128.5M) exceed its short term liabilities ($26.3M).
Long Term Liabilities: CMRX's short term assets ($128.5M) exceed its long term liabilities ($2.5M).
Debt to Equity History and Analysis
Debt Level: CMRX has more cash than its total debt.
Reducing Debt: CMRX had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CMRX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if CMRX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Chimerix current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CMRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CMRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CMRX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CMRX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CMRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mike Sherman (55 yo)
Mr. Michael A. Sherman, also known as Mike, serves as Director at Werewolf Therapeutics, Inc. since May 2021. He has Over 30 years of experience in advancing therapeutics to commercial launch and driving c...
CEO Compensation Analysis
Compensation vs Market: Mike's total compensation ($USD2.10M) is about average for companies of similar size in the US market ($USD1.76M).
Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.
Experienced Management: CMRX's management team is considered experienced (2.7 years average tenure).
Experienced Board: CMRX's board of directors are considered experienced (3.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CMRX insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 38.7%.
Chimerix, Inc.'s employee growth, exchange listings and data sources
- Name: Chimerix, Inc.
- Ticker: CMRX
- Exchange: NasdaqGM
- Founded: 2000
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$490.773m
- Shares outstanding: 86.86m
- Website: https://www.chimerix.com
Number of Employees
- Chimerix, Inc.
- 2505 Meridian Parkway
- Suite 100
- North Carolina
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/12/04 00:03|
|End of Day Share Price||2021/12/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.